Can haloperidol (Haldol) be used to treat a headache?

Haloperidol for Headache Treatment

Haloperidol is highly effective for acute migraine treatment in the emergency department setting, but it is not included in current first-line outpatient migraine guidelines and should be reserved as a rescue medication when standard therapies fail.

Evidence for Haloperidol in Migraine

Emergency Department Use

• Haloperidol 2.5–5 mg IV demonstrates robust efficacy for acute severe migraine in the ED, with 58–80% of patients achieving complete headache resolution within 60–120 minutes 1, 2.

• A 2025 American Headache Society guideline update for ED migraine management does not include haloperidol among the recommended first-line parenteral agents (prochlorperazine, metoclopramide, dexketoprofen, or sumatriptan SC are preferred) 3.

• Haloperidol 5 mg IV was equally effective as metoclopramide 10 mg IV for ED migraine treatment, with significantly fewer patients requiring rescue medications (3% vs 24%, p < 0.02) 4.

• In a placebo-controlled trial, haloperidol 5 mg IV reduced pain scores from 7.7 to 2.2 (vs 7.2 to 6.3 with placebo, p < 0.0001), with 80% achieving significant pain relief compared to 15% with placebo 2.

FDA-Approved Indications

• Haloperidol is FDA-approved only for psychotic disorders, Tourette's disorder, and severe behavior problems in children—headache is an off-label use 5.

Clinical Algorithm for Haloperidol Use in Headache

When to Consider Haloperidol

• Reserve haloperidol for refractory migraine in the ED when patients have failed or cannot tolerate first-line therapies (triptan + NSAID, prochlorperazine, or metoclopramide) 6, 1, 2.

• Consider haloperidol when severe nausea/vomiting accompanies migraine and other antiemetics have been ineffective 6, 4.

Dosing Regimen

• Administer 2.5–5 mg IV diluted in 500 mL normal saline over 15–30 minutes 1, 2.

• Lower doses (2.5 mg) are equally effective as 5 mg and may reduce side effects 1.

• Always co-administer diphenhydramine 25 mg IV to prevent akathisia 4.

Contraindications (Critical Safety Check)

• Do not use haloperidol in patients with:
  • Cardiovascular disease (may cause hypotension or QT prolongation) 5
  • History of seizures (lowers seizure threshold) 5
  • Parkinson's disease or movement disorders 5
  • Known QT prolongation or concurrent QT-prolonging medications 5

Side Effect Profile and Management

Common Adverse Effects

• Akathisia (restlessness) occurs in 43–80% of patients and is the most troublesome side effect 4, 2.

• Sedation is common but generally well-tolerated 6, 2.

• 16% of patients consider side effects intolerable and would refuse future haloperidol treatment 2.

Serious Risks

• Extrapyramidal symptoms can occur but are usually transient and respond to diphenhydramine 6, 2.

• QT prolongation risk exists but was not observed in clinical trials when baseline QTc was normal 1, 4.

• Leukopenia/neutropenia has been reported with chronic use; not relevant for single-dose acute treatment 5.

Why Haloperidol Is Not First-Line

Guideline Recommendations Prioritize Other Agents

• Current 2025 ACP and AHS guidelines recommend triptan + NSAID as first-line outpatient therapy for moderate-to-severe migraine 7, 8, 9.

• For ED parenteral therapy, prochlorperazine IV and metoclopramide IV are preferred over haloperidol based on guideline consensus 3.

• CGRP antagonists (gepants), dihydroergotamine, and lasmiditan are recommended before considering off-label neuroleptics in outpatient settings 7, 9.

Evidence Gaps

• No head-to-head trials compare haloperidol to current first-line ED agents (prochlorperazine, dexketoprofen) in recent guidelines 3.

• All haloperidol migraine studies are ED-based; no evidence supports routine outpatient use 6, 1, 4, 2.

• Long-term safety data for repeated haloperidol use in migraine are lacking 6.

Practical Clinical Pitfalls

• Do not use haloperidol as first-line outpatient therapy—it is not guideline-recommended and carries significant side effect burden 7, 9, 3.

• Do not omit diphenhydramine prophylaxis—akathisia is extremely common without it 4, 2.

• Do not use in patients with cardiovascular risk factors—hypotension and arrhythmia risks outweigh benefits 5.

• Relapse rates are low (7%) but patients should be counseled about recurrence 2.

Summary of Evidence Quality

• High-quality RCT evidence supports haloperidol efficacy for acute migraine in the ED setting 1, 4, 2.

• 2024 narrative review confirms good efficacy for migraine and gastroparesis-related pain 6.

• However, 2025 AHS ED guideline does not include haloperidol in formal recommendations, suggesting expert consensus favors other agents despite positive trial data 3.